PATH-64. Utility of p16 and MTAP Immunohistochemistry as a Surrogate for CDKN2A/B Homozygous Deletion and Prognostic Indicator in Meningiomas
Sign Up to like & getrecommendations! Published in 2025 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaf201.1016
Abstract: The 2021 WHO Classification of CNS Tumors (5th edition) introduced molecular diagnostics into meningioma grading, designating CDKN2A/B homozygous deletion (homo-del) as a criterion for grade 3. Immunohistochemistry (IHC) for p16 (encoded by CDKN2A) and MTAP… read more here.
Keywords: cdkn2a; deletion; homozygous deletion; p16 mtap ... See more keywords